Dr. John Cush RheumNow
5 days 10 hours ago
Gout patients are at greater risk for dementia, sleep apnea, septic arthritis and erectile dysfunction.
For more gout content, follow our Gout: More than Flares campaign at https://t.co/lQoiFjubZJ, https://t.co/p4WQ1GCB68
Dr. John Cush RheumNow
5 days 11 hours ago
The Marriage between Gout and the Kidney
While the link between uric acid and gout was first described by Alfred Baring Garrod in the 1800s, the proof that uric acid might actually be the cause had to await the self-experimentation of two rheumatologists from the University of https://t.co/AWZbjaUtdu
Dr. John Cush RheumNow
5 days 13 hours ago
From 2015-2024, 148 inflam arthritis pts (43 SpA, 35 PsA, 50 RA) w/ a prior cancer were followed 58.1 mos. 24 (19%) had CA recurrence/progression. Post-CA exposure to b/ts-DMARDs did not incr. recurrence risk after adjusting for age & comorbidity burden. https://t.co/MHKIqwyjNN https://t.co/uhOdq1cCPW
Dr. John Cush RheumNow
5 days 13 hours ago
RHEUM SURVEY Q: Which gout drug has the greatest toxicity risk? Answer here>> https://t.co/EQrEjD9237
Dr. John Cush RheumNow
5 days 15 hours ago
SGLT2i use in gout reduces use of gout meds. Study of 26,739 gout pts w/ NIDDM (mean 66 yrs), 67% w/ polypharmacy. SGLT2i (vs DPP-4i) user had less Allopurinol starts (HR 0.62;0.52–0.73), also lower use of steroids (,78), NSAID (.85), colchicine (.87) & diuretics (.87) https://t.co/1dW27YzSvg
Dr. John Cush RheumNow
5 days 16 hours ago
GI dz & malnutrition in scleroderma (SSc) is common, assessed by BMI. Among 450 SSc (F/U 5.3 yrs), lower BMI were significantly assoc w/ pseudoobstruction, smaller oral aperture, higher Medsger vascular severity scores. Defines those at risk https://t.co/w45OhUOUTh https://t.co/hWuIaS6OUe
A recent perspective by Tedeschi tackles many unresolved issues around CPPD diagnosis, classification, and management, including the lack of clinical trials or FDA approved treatments.
William James famously wrote in Pragmatism, “There can be no difference anywhere that doesn’t make a difference elsewhere.” Gout treatment offers a striking medical example of that idea. Drugs prescribed to calm flares or lower uric acid are designed with one primary goal in mind, yet many also produce meaningful effects beyond the joints.
Dr. John Cush RheumNow
6 days 6 hours ago
Metanalysis of 51 studies shows vaccination is suboptimal in Rheum. Influenza Vax rates: RA 50%, SLE 42%, AS 43% & Psa 53%. Pneumococcal vaccinations even lower: 37%, 30%, 39% and 41%. More by with age & comorbidites and by rheumatologists (vs PCPs) https://t.co/3DborC9BLW https://t.co/MPDeJUH0HI
Dr. John Cush RheumNow
6 days 8 hours ago
Gout in Minority Populations
Recent research has revealed substantial racial and ethnic disparities in both who develops gout and the care patients receive. These differences reflect not only genetic susceptibility but also the substantial influence of social determinants of https://t.co/SKEsQVZPw6
Dr. John Cush RheumNow
6 days 10 hours ago
Low dose ASA (81mg or 325mg) increase gout attacks by 81% (RR 1.81). Effect nullified by allopurinol use.
For more gout content, follow our Gout: More than Flares campaign at https://t.co/lQoiFjubZJ, https://t.co/sSm4s3vUtE
Dr. John Cush RheumNow
6 days 11 hours ago
#THA revisions in 3657 RA vs 446428 OA pts (mean F/U ~7y) find RA has signif incr risk of revision (HR 1.35); espec due to infx (HR 1.48), dislocation (1.87), aseptic loosening (0–3m; 2.81). No diff w/ cemented, cementless, hybrid THA. Age > 65 was main risk factor. https://t.co/iK6pL3QF1W
Dr. John Cush RheumNow
6 days 13 hours ago
ACP Position Paper on Dietary Supplements
More than half of U.S. adults use dietary supplements, yet only a quarter use supplements recommended by a healthcare professional, and current law allows supplements to reach the market without a premarket safety evaluation, unlike https://t.co/gwLG4ElfCq

